Powder: -20°C for 3 years | In solvent: -80°C for 1 year
EGFR-IN-33, an acrylamide derivative, is a low-toxicity antitumor agent and a potent inhibitor of EGFR. Among others, overexpression and mutation of the epidermal growth factor receptor (EGFR) has been shown to lead to uncontrolled cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-33 exhibits potential for the study of EGFR mutation-related diseases.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 8-10 weeks | $ 1,520.00 | |
50 mg | 8-10 weeks | $ 1,980.00 | |
100 mg | 8-10 weeks | $ 2,500.00 |
Description | EGFR-IN-33, an acrylamide derivative, is a low-toxicity antitumor agent and a potent inhibitor of EGFR. Among others, overexpression and mutation of the epidermal growth factor receptor (EGFR) has been shown to lead to uncontrolled cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-33 exhibits potential for the study of EGFR mutation-related diseases. |
Molecular Weight | 488.97 |
Formula | C26H25ClN6O2 |
CAS No. | 2711105-59-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
EGFR-IN-33 2711105-59-6 inhibitor inhibit